Results 91 to 100 of about 1,873,489 (255)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Bullous pemphigoid:Serum antibody titre and antigen specificity

, 1995
2 antigens have been identified as possible targets for autoantibody depositions in bullous pemphigoid: a 230-kD protein (BP230) and a 180-kD protein (BP180).
Marcelus C. J. M. de Jong, Jan B. van der Meer, van der Meer, J B, Klaas Heeres, Heeres, K, Hendri H. Pas, Marcel E Jonkman, Pas, H H, Slijper-Pal, I J, de Jong, M C, Ida J. Slijper‐Pal, Jonkman, M F   +11 more
core   +1 more source

Sensitivity, specificity, positive predictive value and negative predictive value of RBD-specific antibody detection by ELISA test.

, 2021
Sensitivity, specificity, positive predictive value and negative predictive value of RBD-specific antibody detection by ELISA test.
Pornsawan Leaungwutiwong (2836934), Narisara Chantratita (33898), Sarunporn Tandhavanant (307947), Viravarn Luvira (5410946), Taniya Kaewarpai (9998258), Sirikamon Koosakunirand (11255998), Watcharapong Piyaphanee (305281)   +6 more
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Quantifying molecular specificity in excipient-driven antibody solubilization

mAbs
Excipients are widely used to suppress the self-association of therapeutic proteins, yet their mechanisms of action are not well understood and often assumed to be nonspecific. Here we show that excipient-mediated solubilization of therapeutic antibodies
Zexiang Han, Nadia A. Erkamp, Rob Scrutton, Giuseppe Licari, Olga Predeina, Andreas Evers, Pietro Sormanni, Tuomas P. J. Knowles   +7 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Optimum sensibility and specificity for each protein and antibody after receiver operating characteristic (ROC) analysis.

, 2018
Optimum sensibility and specificity for each protein and antibody after receiver operating characteristic (ROC) analysis.
Paula de Lima Telmo (6082943), Ângela Nunes Moreira (3143037), Rafael Amaral Donassolo (6082949), Michele Pepe Cerqueira (6082946), Luciana Farias da Costa Avila (6082955), Carolina Georg Magalhães (4646281), Guita Rubinsky Elefant (6082952), Carlos James Scaini (765530), Fábio Pereira Leivas Leite (4868410), Lucas Moreira dos Santos (6082940), Fabricio Rochedo Conceição (3143043)   +10 more
core   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin

Advanced Biomedical Research, 2012
Background: There is a novel hypothesis in that antibodies may have specificity for two distinct antigens that have been named "dual specificity." This hypothesis was evaluated for some defined therapeutic monoclonal antibodies (mAbs) such as Trastuzumab,
Soudabeh Akbarzadeh-Sharbaf, Bagher Yakhchali, Zarrin Minuchehr, Mohammad Ali Shokrgozar, Sirous Zeinali   +4 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source